Abstracts tagged "Cardiovascular disease"

Abstract Number: 1596 • 2015 ACR/ARHP Annual Meeting
Diagnosis of Carotid Plaque By 4 Cardiovascular Risk Scores in Rheumatoid Arthritis
Raymundo Vera-Pineda¹, Alberto Cardenas-de La Garza², Dionicio A. Galarza-Delgado², Jose Ramon Azpiri-Lopez³, Iris J. Colunga-Pedraza², Judith Garcia-Colunga⁴, Guillermo Elizondo⁴, Mario Alberto Garza-Elizondo², Jesus Zacarias Villarreal-Pérez⁵ and Griselda Serna-Peña⁶, ¹Cardiology., Hospital Universitario, UANL., Monterrey, Mexico, ²Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, ³Cardiology, Hospital Universitario, UANL., Monterrey, Mexico, ⁴Radiology, Hospital Universitario, UANL., Monterrey, Mexico, ⁵Endocrinology, Hospital Universitario, UANL., Monterrey, Mexico, ⁶Internal Medicine, Hospital Universitario, UANL., Monterrey, Mexico
Background/Purpose: The leading cause of death in RA is atherosclerotic cardiovascular disease (ASCVD). Traditional risk factors do not explain the increased cardiovascular risk (CVR), which…
Abstract Number: 2170 • 2015 ACR/ARHP Annual Meeting
Sleep Efficiency and Cardiovascular Risk Burden in Rheumatoid Arthritis
Samannaaz S. Khoja¹, Gustavo J. Almeida², Mary Chester M. Wasko³ and Sara R. Piva², ¹Department of Physical Therapy, University of Pittsburgh, Pittsburgh, PA, ²Physical Therapy, University of Pittsburgh, Pittsburgh, PA, ³Lupus Center, Pittsburgh, PA
Background/Purpose: Sleep is an important physiological process responsible for regulating several metabolic and hormonal processes; hence, poor sleep may negatively impact health. Reduced sleep duration…
Abstract Number: 3117 • 2015 ACR/ARHP Annual Meeting
Under-Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease – an International Multicentre Study
Lihi Eder¹, Vinod Chandran¹, Cheryl Rosen², Jan Dutz³, James T. Elder⁴, Proton Rahman⁵, Christopher T. Ritchlin⁶, Francisco A. Tausk⁷, Sherry Rohekar⁸, Richard Hayday⁹, Snezana Barac¹⁰, Devy Zisman¹¹, Joy Feld¹² and Dafna D. Gladman¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴University of Michigan Medical School, Ann Arbor, MI, ⁵Computer Sciences, Memorial University of Newfoundland, St. John's, NF, Canada, ⁶Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁷University of Rochester Medical Center, Rochester, NY, ⁸Western University, London, ON, Canada, ⁹University of Manitoba, Winnipeg, MB, Canada, ¹⁰Winnipeg Clinic, Winnipeg, MB, Canada, ¹¹Rheumatology Unit, Carmel Medical Center, Haifa, Israel, ¹²Carmel Medical Center, Haifa, Israel
Background/Purpose: Cardiovascular risk in patients with psoriatic disease is partly attributed to the high prevalence of traditional cardiovascular risk factors in these patients. This study…
Abstract Number: 460 • 2015 ACR/ARHP Annual Meeting
Changes in Body Composition and Metabolic Profile during Treatment with Tocilizumab in Patients with Rheumatoid Arthritis
Anne Tournadre¹, Bruno Pereira², Frederic Dutheil³, Vincent Sapin⁴, Charlotte Giraud⁵, Sandrine Malochet-Guinamand⁶, Thomas Frayssac⁷, Sylvain Mathieu⁵, Jean-Jacques Dubost⁸ and Martin Soubrier⁸, ¹Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Biostatistics unit (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France, ³Preventive and Occupational Medicine, CHU G. Montpied Laboratory of Metabolic Adaptations to Exercise in Physiological and Pathological conditions EA3533, Clermont-Ferrand, France, ⁴Biochemistry and Molecular Biology Department CHU Clermont-Ferrand, Clermont Université, Université d'Auvergne, EA7281, Clermont-Ferrand, France, ⁵Rheumatology, Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁶Rheumatology Department,, Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁷Rheumatology, Rheumatology department CHU Clermont-Ferrand, Clermont-ferrand, France, ⁸Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France
Background/Purpose: Rheumatoid arthritis (RA) is characterized by increased cardiovascular risk and metabolic changes including cachectic obesity, insulin resistance, dyslipidemia. DMARDs decrease inflammation and could thus…
Abstract Number: 1510 • 2015 ACR/ARHP Annual Meeting
The Association Between HDL Cholesterol Efflux Capacity, Citrullinated ApoA1 and Anti-Citrullinated ApoA1 Antibodies in Rheumatoid Arthritis
Katherine Liao¹, Jing Cui¹, Christopher Rhodes², Lauren J. Lahey², Martin Playford³, I-Hsin Kuo¹, Michelle Frits¹, Christine Iannaccone¹, Jonathan S. Coblyn⁴, Michael Weinblatt¹, Nancy Shadick⁵, Nehal N. Mehta³ and Jeremy Sokolove², ¹Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ²Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, ³NHLBI, National Institutes of Health, Bethesda, MD, ⁴Brigham & Women's Hospital, Boston, MA, ⁵Division of Rheumatology, Immunology & Allergy, Brigham & Women's Hospital, Boston, MA
Background/Purpose: High density lipoprotein (HDL) cholesterol efflux capacity measures how well HDL particles remove cholesterol from lipid-laden macrophages, such as those found in atherosclerotic plaques. …
Abstract Number: 1608 • 2015 ACR/ARHP Annual Meeting
Protective Role of the Vitamin D Receptor Apai (rs7975232) Polymorphism Against Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis from Northern Spain
Raquel López-Mejías¹, Fernanda Genre¹, Sara Remuzgo-Martínez¹, Gema Robledo², Begoña Ubilla¹, Veronica Mijares¹, Javier Llorca³, Montserrat Robustillo-Villarino⁴, Alfonso Corrales¹, Carlos González-Juanatey⁵, Jose A. Miranda-Filloy⁶, Trinitario Pina⁷, Ricardo Blanco⁷, Esther Vicente⁸, Juan José Alegre⁹, Cesar Magro¹⁰, Enrique Raya¹¹, Beatriz Tejera¹², Marco A Ramírez Huaranga¹³, Ivan Ferraz-Amaro¹², Santos Castañeda¹⁴, Javier Martín² and Miguel A. Gonzalez-Gay^1,15, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Institute of Parasitology and Biomedicine López-Neyra, IPBLN-CSIC, Granada, Spain, ³Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁴Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, ⁵Cardiology Division, Hospital Lucus Augusti, Lugo, Spain, ⁶Rheumatology Division, Hospital Lucus Augusti, Lugo, Spain, ⁷Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁸Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, ⁹Rheumatology, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁰Rheumatology Department, Hospital Clínico San Cecilio, Granada, Spain, ¹¹Rheumatology, Hospital Clínico San Cecilio, Granada, Spain, ¹²Rheumatology Division, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹³Rheumatology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹⁴Rheumatology, H.U. La Princesa, Madrid, Spain, ¹⁵Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Several vitamin D receptor (VDR) polymorphisms have been associated with cardiovascular (CV) and autoimmune diseases. Carotid plaques are surrogate markers of severe atherosclerotic disease.…
Abstract Number: 2200 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository Cluster Analysis: Identification of Different Clinical Phenotypes Among Antiphospholipid Antibody-Positive Female Patients
Stephane Zuily¹, Cecilia B. Chighizola², DENIS WAHL¹, Pier Luigi Meroni³ and Doruk Erkan⁴, ¹CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, France, Nancy, France, ²Department of Clinical Sciences and Community Health, University of Milan, Istituto Auxologico Italiano, Cusano Milanino, Italy, ³University of Milan, Department of Clinical Sciences and Community Health, Division of Rheumatology, Gaetano Pini Institute, Milan, Italy, ⁴Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY
Background/Purpose: APS ACTION International Clinical Database and Repository was created to study the natural course of persistently antiphospholipid antibodies (aPL)-positive patients ± autoimmune disorders over…
Abstract Number: 3120 • 2015 ACR/ARHP Annual Meeting
The Prevalence, Incidence and Management of Hypertension, Diabetes and Hyperlipidemia in Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis
Kashif Jafri¹, Christie M. Bartels², Daniel Shin³ and Alexis Ogdie-Beatty⁴, ¹Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Pennsylvania, Philadelphia, PA, ⁴Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriasis, psoriatic arthritis (PsA), and rheumatoid arthritis (RA) are associated with an increased risk for cardiovascular disease (CVD). While management of traditional CVD risk…
Abstract Number: 473 • 2015 ACR/ARHP Annual Meeting
Methotrexate, Blood Pressure and Arterial Wave Reflection in Rheumatoid Arthritis
Leena R Baghdadi^1,2,3, Richard J Woodman², E Michael Shanahan⁴ and Arduino A Mangoni³, ¹Department of Family and Community Medicine, King Saud University, Riyadh, Saudi Arabia, ²Flinders Centre for Epidemiology and Biostatistics, Flinders University, Adelaide, Australia, ³Department of Clinical Pharmacology, Flinders University, Adelaide, Australia, ⁴Department of Rheumatology, Flinders University, Adelaide, Australia
Background/Purpose: Methotrexate (MTX) use has been associated with reduced cardiovascular morbidity and mortality in patients with rheumatoid arthritis (RA). Although MTX has anti-inflammatory effects, there…
Abstract Number: 1515 • 2015 ACR/ARHP Annual Meeting
Accounting for Rheumatoid Arthritis in the Determination of 10 Year Cardiovascular Risk
Rupal Chavda and Rochella A. Ostrowski, Rheumatology, Loyola University Medical Center, Maywood, IL
Background/Purpose: Patients with rheumatoid arthritis (RA) carry a higher risk for cardiovascular disease (CVD) independent of traditional risk factors. In this study, we set out…
Abstract Number: 1609 • 2015 ACR/ARHP Annual Meeting
Lack of Association Between ZHX2, Lepr, Gckr and ASCL1 and Carotid Intima-Media Thickness, Carotid Plaques and Cardiovascular Disease in Patients with Rheumatoid Arthritis
Raquel López-Mejías¹, Fernanda Genre¹, Sara Remuzgo-Martínez¹, Montserrat Robustillo-Villarino², Alfonso Corrales¹, Javier Llorca³, Carlos González-Juanatey⁴, Begoña Ubilla¹, Jose A. Miranda-Filloy⁵, Veronica Mijares¹, Trinitario Pina⁶, Ricardo Blanco⁶, Juan José Alegre², Marco A Ramírez Huaranga⁷, Maria D Mínguez Sánchez⁷, Carmen Gomez Vaquero⁸, Luis Rodriguez Rodriguez⁹, Benjamin Fernandez Gutierrez⁹, Alejandro Balsa¹⁰, Dora Pascual-Salcedo¹⁰, Francisco Lopez Longo¹¹, Patricia E. Carreira¹², Cesar Magro¹³, Enrique Raya¹⁴, Beatriz Tejera¹⁵, Ivan Ferraz-Amaro¹⁵, Esther Vicente¹⁶, Isidoro González-Alvaro¹⁶, Santos Castañeda¹⁷, Javier Martín¹⁸ and Miguel A. Gonzalez-Gay^1,19, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, ³Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁴Cardiology Division, Hospital Lucus Augusti, Lugo, Spain, ⁵Rheumatology Division, Hospital Lucus Augusti, Lugo, Spain, ⁶Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁷Rheumatology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ⁸Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁹Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ¹⁰Department of Rheumatology, Hospital La Paz, Madrid, Spain, ¹¹Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹²Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ¹³Rheumatology Department, Hospital Clínico San Cecilio, Granada, Spain, ¹⁴Rheumatology, Hospital Clínico San Cecilio, Granada, Spain, ¹⁵Rheumatology Division, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁶Rheumatology Department, Hospital Universitario la Princesa, IIS-Princesa, Madrid, Spain, ¹⁷Rheumatology, H.U. La Princesa, Madrid, Spain, ¹⁸Institute of Parasitology and Biomedicine López-Neyra, IPBLN-CSIC, Granada, Spain, ¹⁹Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Rheumatoid arthritis (RA) is a polygenic disease associated with accelerated atherosclerosis and increased cardiovascular (CV) mortality. Recent studies have identified the ZHX2 rs11781551 polymorphism…
Abstract Number: 2243 • 2015 ACR/ARHP Annual Meeting
Economic Burden of Controlled Gout, Uncontrolled Gout, and Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey
Robert Morlock¹, Natalia M. Flores², Kathy Annunziata³, Jonathan Chapnick⁴ and Javier Nuevo⁵, ¹4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ²Kantar Health, Foster City, CA, ³Kantar Health, Princeton, NJ, ⁴Kantar Health, Horsham, PA, ⁵AstraZeneca, Madrid, Spain, Madrid, Spain
Background/Purpose: Gout is one of the most common forms of inflammatory arthritis and is caused by chronic high serum uric acid (sUA) levels (ie, hyperuricemia),…
Abstract Number: 3138 • 2015 ACR/ARHP Annual Meeting
Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis
Giacomo De Luca¹, Silvia Laura Bosello¹, Francesca Gabrielli², Giorgia Berardi¹, Federico parisi¹, Manuela Rucco¹, Giovanni Canestrari¹, Leonarda Galiuto³, Filippo Crea³, Francesco Loperfido² and Gianfranco Ferraccioli¹, ¹Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²Division of Heart Failure and Cardiac Rehabilitation, Catholic University - Rome, Rome, Italy, ³Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Heart involvement is common during Systemic Sclerosis (SSc), even if often clinically silent, and represents the leading cause of death in about one third…
Abstract Number: 35 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis As a Risk Factor for Cardiovascular Events Following Hospitalized Pneumonia; A Population-Based Cohort Study
Mette Holland-Fischer¹, Ulrik Tarp², Reimar W. Thomsen³ and Mette Nørgaard³, ¹Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ²Department of Rheumatology, Aarhus University Hospital, AArhus, Denmark, ³Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Cardiovascular disease is a major cause of morbidity and mortality in patients with Rheumatoid Arthritis (RA). Patients with RA do also have an increased…
Abstract Number: 808 • 2015 ACR/ARHP Annual Meeting
Heritable Endotheliopathy and ApolipoproteinL1 Risk Traits in SLE
Ashira Blazer¹, Andrew Markham², Sara Rasmussen³, Jill P. Buyon⁴, H. Michael Belmont⁵, Shilpi Mehta-Lee⁶, Janet Nwaukoni⁴, Peter M. Izmirly⁷ and Robert Clancy⁴, ¹Division of Rheumatology, NYU School of Medicine, New York, NY, ²Medicine, New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵Hosp for Joint Disease, New York, NY, ⁶Obstetrics and Gynecology, New York University School of Medicine, New York, NY, ⁷Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: With higher prevalence of renal and cardiovascular diseases (CVD), as well as HTN, African American (AA) SLE patients experience accelerated damage accrual and excess…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].